Congratulations to @BritJClinPharm on the launch of this virtual issue! @KimScarsi & Mona Loutfy co-guest editors. Stay tuned for a dedicated issue to be published in June!
To mark International Transgender Day of Visibility on 31 March, the BJCP launched a virtual issue on Pharmacological Considerations for Trans and Gender Diverse Populations. https://t.co/8u8Bdsz5Rk #TDOV2024
This year's edition of the Nurses & Pharmacists HIV Clinical Forum is almost here! Don't forget to sign up:
https://t.co/Q8a6azxMGz
#NURHCF#PHAHCF#HIVCF@Academic_MedEdu
@LoutfyDr @KimScarsi @BritJClinPharm We are seeking original research articles and review articles that explore advances in trans care, including optimization of gender-affirming hormone therapy (GAHT) and sexually transmitted and blood-borne infections (STBBI) preventative and treatment strategies.
Together with @LoutfyDr and @KimScarsi, we are proud to launch a themed issue on Trans & Gender Diverse Populations @BritJClinPharm as part of Transgender Awareness Week. The issue will be released on March 31, 2024, Intl Transgender Day of Visibility https://t.co/DoHA3KKk2f
24 hours to go until LMAP 2023! Last chance to register for free - a programme not to be missed and now with Royal College of Physicians CPD accreditation!
Register ➡️ https://t.co/E2fGAkuJM5
So very sad to hear of Ron’s passing; He was such a giant and a force for change. Deepest condolences to his family, friends, colleagues and the community.
It is with a heavy heart that we share that Ron Rosenes, champion of research and tireless advocate for those living with HIV, died on October 21, 2023. CAHR extends its deepest condolences to Ron’s family, and to all those who were fortunate enough to know him. (1/2)
It is with a heavy heart that we share that Ron Rosenes, champion of research and tireless advocate for those living with HIV, died on October 21, 2023. CAHR extends its deepest condolences to Ron’s family, and to all those who were fortunate enough to know him. (1/2)
Join us on Wednesday 8th November for LMAP 2023! Lots of engaging talks and cases around antiretroviral pharmacology and COVID-19 therapeutics. Programme and free registration: https://t.co/6qdip5B3hZ
🔬 Join the 6th Annual Nurses & Pharmacists #HIV Clinical Forum 2023!
Connect with experts, join plenary lectures, Q&A sessions, all in a program tailored for #nurses, #pharmacists, and other dedicated HIV #healthcareprofessionals!
Registration now OPEN: https://t.co/fB5YJRt9FP
Really important work. We are always looking for efficient and accurate ways for #PK sampling in the community, and this abstract gave valuable insights into how to evaluate such devices. @AcutePete#AtTheEquatorUG#AntiviralPK@aeolagunju
Rome wasn't built in a day...and neither was the #AntiviralPK workshop! Congratulations to Mattia Berton for Best Abstract Award! What a great meeting and can't wait until next year in...Liverpool!!! Thank you all and to @Academic_MedEdu@AlicePharmd @KimScarsi
PrEP in TGW in blood and rectum was the subject of an abstract presentation at #AntiviralPK from @CPACLab. FHT may alter PrEP PK and in this study, FHT hadn't decreased pooled TFV or FTC in either blood or rectum and estradiol wasn't correlated with PrEP concentrations.
NMV/r with MPV for COVID in saliva, tear, and nasal was discussed at #AntiviralPK. The AGILE CST-8 study noted NMV penetrates into tears and nasal compartments and aligned well with previous studies. 100% of tear and nasal concentrations were above PK thresholds. BOLO for more!
Examining RMD for HIV-1 latency and its PK endpoints? We learned in an abstract presentation at #AntiviralPK from @CPACLab through a comprehensive dose fractionation study that time correlates with HIV transcription. In the hollow fiber model, Time>EC90 correlated as well.
The issues are the tissues! Dr. Charles Flexner at the #AntiviralPK workshop discussed the knowledge gaps related to tissue-specific pharmacology. By using LSD and sildenafil as pharmacological examples, we have learned the tissue-specific PK/PD may not be reflected in plasma.
Does tissue pharmacology matter? Dr. Saye Khoo at #AntiviralPK provided a comprehensive analysis of PK/PD in the tissues. This is a large and complex topic so huge kudos for the overview. Many more questions remain, especially as we enter a new era in ART!
@VirTUAL_UoL#Pharmacometrics lead Paolo Denti from @UCT_news using our atazanavir/ritonavir + rifampicin #DDI data to illustrate controversies in interpretation. Some targets became 'set in stone' years ago based on scanty data; now we understand more, reflection is necessary.